Intellipharmaceutics International Inc (IPCI) 2.49 $IPCI
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 10:14AM CDT
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert
5 Stocks Ready for Breakouts
at The Street - Mon Jul 28, 8:16AM CDT
These stocks look poised to break out and trade higher from current levels.
Why Intellipharmaceutics (IPCI) Stock Is Down Today
at The Street - Wed Jul 09, 2:41PM CDT
Intellipharmaceutics (IPCI) plunged Wednesday after Maxim Group downgraded the stock to "hold" from "buy" and decreased its price target to $3 from $7.
IntelliPharmaCeutics International (IPCI) Crumbles: Stock Plunges by 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:30AM CDT
IntelliPharmaCeutics International has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Intellipharmaceutics Announces Second Quarter 2014 Results
GlobeNewswire - Mon Jul 07, 5:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes
PR Newswire - Fri Mar 21, 4:39PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at:
IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day.
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:44AM CDT
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue?
4 Stocks Under to Trade for Breakouts
at The Street - Fri Mar 21, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014
GlobeNewswire - Wed Mar 19, 4:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has sent to registered shareholders an amended form of proxy for voting at its annual and special shareholders meeting to be held on March 27, 2014 (the "Meeting"
.
Correction - Mackie Research Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Mon Mar 17, 9:59AM CDT
Vancouver, BC, March 17, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.
Jennings Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Fri Mar 14, 5:22PM CDT
Vancouver, BC, March 14, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.
Intellipharmaceutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Mar 04, 4:00PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences.
Intellipharmaceutics posts higher net loss in 2013
M2 - Wed Feb 19, 6:11AM CST
Canadian pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Tuesday a net loss of USD11.5m (USD0.58 per common share) for the year ended 30 November 2013.
Intellipharmaceutics Announces 2013 Year End Results
GlobeNewswire - Tue Feb 18, 6:05AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2013. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)
Intellipharmaceutics International Inc awarded first profit-share of USD3.1m from Par Pharmaceuticals Inc for sales of 15 and 30 mg generic Focalin XR
M2 - Tue Feb 04, 4:33AM CST
Pharmaceutical company Intellipharmaceutics International Inc (TSX:I) said on Monday that it has received the first payment of USD3.1m relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its licensee Par Pharmaceutical Inc.
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 29, 10:14AM CDT
IntelliPharmaCeutics (IPCI): Moving Average Crossover Alert
5 Stocks Ready for Breakouts
at The Street - Mon Jul 28, 8:16AM CDT
These stocks look poised to break out and trade higher from current levels.
Why Intellipharmaceutics (IPCI) Stock Is Down Today
at The Street - Wed Jul 09, 2:41PM CDT
Intellipharmaceutics (IPCI) plunged Wednesday after Maxim Group downgraded the stock to "hold" from "buy" and decreased its price target to $3 from $7.
IntelliPharmaCeutics International (IPCI) Crumbles: Stock Plunges by 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 7:30AM CDT
IntelliPharmaCeutics International has seen flat earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Intellipharmaceutics Announces Second Quarter 2014 Results
GlobeNewswire - Mon Jul 07, 5:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2014. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes
PR Newswire - Fri Mar 21, 4:39PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at:
IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day.
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:44AM CDT
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue?
4 Stocks Under to Trade for Breakouts
at The Street - Fri Mar 21, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014
GlobeNewswire - Wed Mar 19, 4:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has sent to registered shareholders an amended form of proxy for voting at its annual and special shareholders meeting to be held on March 27, 2014 (the "Meeting"
. Correction - Mackie Research Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Mon Mar 17, 9:59AM CDT
Vancouver, BC, March 17, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.
Jennings Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Fri Mar 14, 5:22PM CDT
Vancouver, BC, March 14, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.
Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.
Intellipharmaceutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Mar 04, 4:00PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences.
Intellipharmaceutics posts higher net loss in 2013
M2 - Wed Feb 19, 6:11AM CST
Canadian pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Tuesday a net loss of USD11.5m (USD0.58 per common share) for the year ended 30 November 2013.
Intellipharmaceutics Announces 2013 Year End Results
GlobeNewswire - Tue Feb 18, 6:05AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2013. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)
Intellipharmaceutics International Inc awarded first profit-share of USD3.1m from Par Pharmaceuticals Inc for sales of 15 and 30 mg generic Focalin XR
M2 - Tue Feb 04, 4:33AM CST
Pharmaceutical company Intellipharmaceutics International Inc (TSX:I) said on Monday that it has received the first payment of USD3.1m relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its licensee Par Pharmaceutical Inc.
